| Released | Contributor | Author | Title | Pages | Price |
|---|
| May 1, 2013 | New Constructs, LLC | N/A | ACCL: Due Diligence Review: Forensic Earnings and Valuation | 13 | $25 | | May 1, 2013 | ValuEngine, Inc. | N/A | ValuEngine Detailed Valuation Report for ACCL | 11 | $126.50 | | May 1, 2013 | ValuEngine, Inc. | N/A | ValuEngine Industry Report for Business Software Svcs/bpo | 17 | $195.50 | | Apr 12, 2013 | Wright Reports | N/A | Wright Investors Service Comprehensive Report for Accelrys, Inc. | 41 | $471.50 | | Apr 28, 2013 | Alpha Street Research | Hunter Orr | ACCL - Accelrys Inc - Downgraded to a Sell - Research Report by ASR | 9 | $24 | | Apr 28, 2013 | Pechala's Reports | Lubomir Pechala | PHARMACOPEIA INC (ACCL) - REPORT FOR ACTIVE TRADERS | 1 | $25 | | Apr 28, 2013 | Market Edge | N/A | Market Edge Equity Research Report | 4 | $10 | | Apr 27, 2013 | Pechala's Reports | Frantisek Pechala | PHARMACOPEIA INC (ACCL) 12-months forecast | 1 | $15 | | Apr 18, 2013 | Jefferson Research | N/A | Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ACCELRYS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 11 | $20 | | Apr 25, 2013 | Ford Investor Services, Inc. | N/A | Industry Value Graph: ACCL , ANAC , PBH , TARO , TGX , VVUS -- DRUGS | 3 | $34.50 |
|
View All Reports for ACCL ... |
|
|
0.23(2.82%) 3:59PM EDT - Nasdaq Real Time Price